SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 25, 2002
SALIX PHARMACEUTICALS, LTD.
--------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware
- --------------------------------------------------------------------------------
(State or other jurisdiction of incorporation)
000-23265 94-3267443
- ------------------------------------- --------------------------------------
(Commission file Number) (IRS Employer ID Number)
8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina 27615
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (919) 862-1000
----------------------------
Item 5. Other Events and Regulation FD Disclosure
On February 25, 2002, Salix Pharmaceuticals announced that its New Drug
Application for Lumenax(TM) (rifiximin) has been accepted for filing with the
U.S. Food and Drug Administration.
A copy of this press release is attached as an exhibit.
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SALIX PHARMACEUTICALS, LTD.
Date: February 25, 2002 By: /s/ Adam C. Derbyshire
------------------------
Adam C. Derbyshire
Vice President and Chief Financial
Officer